The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Beamion LUNG-1: PROs with zongertinib in HER2-mutant advanced NSCLC
Joshua Sabari, MD, New York University Langone Health, New York, NY, discusses patient-reported outcome (PRO) data from the Beamion LUNG-1 trial (NCT04886804) of first-line zongertinib in patients with HER2-mutant advanced non-small cell lung cancer (NSCLC). Results demonstrated rapid and sustained improvements in physical functioning and disease-related symptoms from early in treatment, with a high proportion of PRO responders and low overall side-effect burden, reflecting the well-tolerated profile of this selective HER2 inhibitor. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
